Skip to main content
. 2018 Aug 10;16(4):5473–5481. doi: 10.3892/ol.2018.9291

Figure 3.

Figure 3.

Effect of MK-1775 on the apoptosis of acute lymphoblastic leukemia cells. (A) Nalm-6 and Jurkat were treated with 0, 100 and 300 nM MK-1775 for 48 h. Flow cytometry was used to detect the apoptotic cells. Annexin V-FITC-positive cells were considered as apoptotic. Values are presented as mean ± standard deviation. Results are representative of 3 independent experiments. *P<0.05 compared with 0 nM, #P>0.05 compared with 100 nM group, ##P<0.05 compared with 100 nM group. (B) Nalm-6 and Jurkat cells were treated with control, 100 nM MK-1775, 0.05 mg/ml ADM or the combination for 24 h. Flow cytometry was used to detect apoptotic cells. Values are presented as mean ± standard deviation. Results are representative of 3 independent experiments. MK-1775 combined with doxorubicin induced higher apoptotic rates compared with each single agent and the control in the Nalm-6 and Jurkat cell lines (*P<0.05 compared with#). FITC, fluorescein isothiocyanate; PI propidium iodide; ADM, doxorubicin.